Mast cells play a protumorigenic role in primary cutaneous lymphoma

Blood

Volumn 120, Issue 10, 2012, Pages 2042-2054

  Rabenhorst, Anja ^a   Schlaak, Max ^a   Heukamp, Lukas C ^a   Förster, Anja ^a   Theurich, Sebastian ^a   Von Bergwelt Baildon, Michael ^a   Büttner, Reinhard ^a   Kurschat, Peter ^a   Mauch, Cornelia ^a   Roers, Axel ^b   Hartmann, Karin ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL INFILTRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LARGE CELL LYMPHOMA; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; SKIN BIOPSY; SKIN LYMPHOMA; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84866166517     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-415638     Document Type: Article

References (57)

1. Willemze R, Dreyling M, ESMO Guidelines Working Group. Primary cutaneous lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl 4):115-118.
2. Stadler R, Assaf C, Klemke C-D, et al. Short German guidelines: Cutaneous lymphomas. J Dtsch Dermatol Ges. 2008;6:S25-S31.
3. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-3785.
4. Hanahan D, Weinberg R. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
5. Cirée A, Michel L, Camilleri-Bröet S, et al. Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and sezary syndrome). Int J Cancer. 2004;112(1):113-120.
6. Krejsgaard T, Ralfkiaer U, Clasen-Linde E, et al. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway. J Invest Dermatol. 2011;131(6):1331-1338.
7. Wu X, Sells RE, Hwang ST. Up-regulation of inflammatory cytokines and oncogenic signal pathways preceding tumor formation in a murine model of T-cell lymphoma in skin. J Invest Dermatol. 2011;131(8):1727-1734.
8. Shelburne CP, Abraham SN. The mast cell in innate and adaptive immunity. Adv Exp Med Biol. 2011;716:162-185.
9. Tsai M, Grimbaldeston M, Galli SJ. Mast cells and immunoregulation/ immunomodulation. Adv Exp Med Biol. 2011;716:186-211.
10. Ribatti D, Crivellato E. Mast cells, angiogenesis and cancer. Adv Exp Med Biol. 2011;716:270-288.
11. Wasiuk A, De Vries VC, Hartmann K, Roers A, Noelle RJ. Mast cells as regulators of adaptive immunity to tumours. Clin Exp Immunol. 2009;155(2):140-146.
12. Pittoni P, Tripodo C, Piconese S, et al. Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res. 2011;71(18):5987-5997.
13. Melillo RM, Guarino V, Avilla E, et al. Mast cells have a protumorigenic role in human thyroid cancer. Oncogene. 2010;29(47):6203-6215.
14. Ribatti D, Ennas MG, Vacca A, et al. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest. 2003;33(5):420-425.
15. Molin D, Edström A, Glimelius I, et al. Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Haematol. 2002;119(1):122-124.
16. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science. 2002;296(5569):920- 922.
17. Terada T, Matsunaga Y. Increased mast cells in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Hepatol. 2000;33(6):961-966.
18. Ribatti D, Vacca A, Marzullo A, et al. Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Int J Cancer. 2000;85(2):171-175.
19. Takanami I, Takeuchi K, Naruke M. Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer. 2000;88(12):2686-2692.
20. Tan SY, Fan Y, Luo HS, Shen ZX, Guo Y, Zhao LJ. Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer. World J Gastroenterol. 2005;11(8):1210-1214.
21. Rajput A, Turbin D, Cheang M, et al. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat. 2008;107(2):249-257.
22. Amini R-M, Aaltonen K, Nevanlinna H, et al. Mast cells and eosinophils in invasive breast carcinoma. BMC Cancer. 2007;7(1):165.
23. Scholten J, Hartmann K, Gerbaulet A, et al. Mast cell-specific Cre/loxP-mediated recombination in vivo. Transgenic Res. 2008;17(2):307-315.
24. Dudeck A, Dudeck J, Scholten J, et al. Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens. Immunity. 2011;34(6):973-984.
25. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713-1722.
26. Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29(18):2598-2607.
27. Kadin ME, Cavaille-Coll MW, Gertz R, Massagué J, Cheifetz S, George D. Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc Natl Acad Sci U S A. 1994;91(13):6002-6006.
28. Kaltoft K, Bisballe S, Dyrberg T, Boel E, Rasmussen PB, Thestrup-Pedersen K. Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides. In Vitro Cell Dev Biol. 1992;28A(3 Pt 1):161-167.
29. Kaltoft K, Bisballe S, Rasmussen HF, Thestrup-Pedersen K, Thomsen K, Sterry W. A continuous T-cell line from a patient with Sézary syndrome. Arch Dermatol Res. 1987;279(5):293-298.
30. Klein G, Lindahl T, Jondal M, et al. Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas. Proc Natl Acad Sci U S A. 1974;71(8):3283-3286.
31. Schneider U, Schwenk HU, Bornkamm G. Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer. 1977;19(5):621-626.
32. Drube S, Heink S, Walter S, et al. The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells. Blood. 2010;115(19):3899-3906.
33. McKenzie RCT, Jones CL, Tosi I, Caesar JA, Whittaker SJ, Mitchell TJ. Constitutive activation of STAT3 in Sezary syndrome is independent of SHP-1. Leukemia. 2012;26(2):323-331.
34. Grimbaldeston MA, Chen C-C, Piliponsky AM, Tsai M, Tam S-Y, Galli SJ. Mast-cell deficient W-sash c-kit Mutant KitW-sh/W-sh Mice as a model for investigating mast cell biology in vivo. Am J Pathol. 2005;167(3):835-848.
35. Buch T, Heppner FL, Tertilt C, et al. A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin administration. Nat Methods. 2005;2(6):419-426.
36. Töyry S, Fräki J, Tammi R. Mast cell density in psoriatic skin. The effect of PUVA and corticosteroid therapy. Arch Dermatol Res. 1988;280(5):282-285.
37. Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187(1):490-500.
38. Jiang WY, Chattedee AD, Raychaudhuri SP, Raychaudhuri SK, Farber EM. Mast cell density and IL-8 expression in nonlesional and lesional psoriatic skin. Int J Dermatol. 2001;40(11):699-703.
39. Ackermann L, Harvima IT. Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-alpha and their degranulation is associated with expression of ICAM-1 in the epidermis. Arch Dermatol Res. 1998;290(7):353-359.
40. Nico B, Mangieri D, Crivellato E, Vacca A, Ribatti D. Mast cells contribute to vasculogenic mimicry in multiple myeloma. Stem Cells Dev. 2008;17(1):19-22.
41. Strouch MJ, Cheon EC, Salabat MR, et al. Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res. 2010;16(8):2257-2265.
42. Tóth-Jakatics R, Jimi S, Takebayashi S, Kawamoto N. Cutaneous malignant melanoma: Correlation between neovascularization and peritumor accumulation of mast cells overexpressing vascular endothelial growth factor. Hum Pathol. 2000;31(8):955-960.
43. Medina VA, Rivera ES. Histamine receptors and cancer pharmacology. Br J Pharmacol. 2010;161(4):755-767.
44. Ruffell B, Coussens LM. Histamine restricts cancer: nothing to sneeze at. Nat Med. 2011;17(1):43-44.
45. Rivera ES, Cricco GP, Engel NI, Fitzsimons CP, Martín GA, Bergoc RM. Histamine as an autocrine growth factor: an unusual role for a widespread mediator. Semin Cancer Biol. 2000;10(1):15-23.
46. Bolton E, King J, Morris DL. H2-antagonists in the treatment of colon and breast cancer. Semin Cancer Biol. 2000;10(1):3-10.
47. Krejsgaard T, Vetter-Kauczok CS, Woetmann A, et al. Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia. 2006;20(10):1759-1766.
48. Vacca A, Moretti S, Ribatti D, et al. Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9. Eur J Cancer. 1997;33(10):1685-1692.
49. Kopp KLM, Kauczok CS, Lauenborg B, et al. COX-2-dependent PGE2 acts as a growth factor in mycosis fungoides (MF). Leukemia. 2010;24(6):1179-1185.
50. Enblad G, Sundstrom C, Glimelius B. Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis. Hematol Oncol. 1993;11(4):187-193.
51. Tomita M, Matsuzaki Y, Onitsuka T. Effect of mast cells on tumor angiogenesis in lung cancer. Ann Thorac Surg. 2000;69(6):1686-1690.
52. Elpek GÖ, Gelen T, Aksoy NH, et al. The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus. J Clin Pathol. 2001;54(12):940-944.
53. Karpova MB, Fujii K, Jenni D, Dummer R, Urosevic-Maiwald M. Evaluation of lymphangiogenic markers in Sézary syndrome. Leuk Lymphoma. 2011;52(3):491-501.
54. Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol. 2008;8(6):478-486.
55. Nigrovic PA, Gray DHD, Jones T, et al. Genetic inversion in mast-cell deficient Wsh mice interrupts corin and manifests as hematopoietic and cardiac aberrancy. Am J Pathol. 2008;173(6):1693-1701.
56. Starkey JR, Crowle PK, Taubenberger S. Mast-cell-deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer. 1988;42(1):48-52.
57. van Hall T, van Bergen J, van Veelen PA, et al. Identification of a novel tumor-specific CTL epitope presented by RMA, EL-4, and MBL-2 lymphomas reveals their common origin. J Immunol. 2000;165(2):869-877.